In this interview, Douglas L. Mann and Javed Butler discuss the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial and whether the risk of heart failure (HF) modulates the effectiveness of empagliflozin on HF hospitalization or cardiovascular death in patients with type 2 diabetes without HF.

Subscribe on iTunes | Subscribe on Google Play | Subscribe to ACCEL

Keywords: Heart Failure, Diabetes Mellitus, Diabetes Mellitus, Type 2, Metabolic Syndrome, Primary Prevention, Secondary Prevention, ACCELLite

< Back to Listings